In this study, by analysing hADA3 distribution in breast cancer tumour samples, they demonstrated that predominant nuclear localization of hADA3 in breast cancer tissues correlates with ER expression and together can serve as helpful markers of prognosis, whereas predominant cytoplasmic hADA3 expression correlates with ErbB2+/EGFR+ expression and together may be used for poor prognosis. This evidence concerns the gene TADA3 and breast carcinoma.